Skip to main content

Table 1 Baseline patient demographics and clinical characteristics

From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Characteristic

Erlotinib

GC

P value

Median age at diagnosis (years)

60.17 ± 13.31

58.75 ± 12.12

0.71

Gender, n (%)

  

0.68

Male

6 (6/12, 50.00 %)

8 (8/12, 66.67 %)

 

Female

6 (6/12, 50.00 %)

4 (4/12, 33.33 %)

 

Smoking duration

6.25 ± 11.89

20.83 ± 21.09

0.10

Daily cigarette consumption, n

7.92 ± 14.99

17.92 ± 18.27

0.18

Pathology, n (%)

  

1.00

Adeno

11 (11/12, 91.67 %)

11 (11/12, 91.67 %)

 

LCNEC

0 (0.00 %)

1 (1/12, 8.33 %)

 

Adenoid cystic carcinoma

1 (1/12, 8.33 %)

0 (0.00 %)

 

Mutation status, n (%)

  

<0.001

EGFR/KRAS wild type

0

11

 

KRAS

0

1

 

Exon 19 deletion

6

0

 

L858R

4

0

 

EGFR mutation with KRAS codon

1

0

 

12/13*

   

EGFR mutation with EML4-ALK*

1

0

 

Deletion in BIM

2/8

0/9

 

Postoperative radiotherapy, n

3/6

2/7

0.59

Median follow-up (months)

19.3 (5.8–64.0)

35.6 (1.7–68.7)

0.41

  1. EGFR epidermal growth factor receptor, LCNEC large-cell neuroendocrine carcinoma, GC gemcitabine/carboplatin, BIM Bcl-2-interacting mediator of cell death
  2. *Two patients in the erlotinib arm with the EGFR L855R mutation also had the KRAS mutation or EML4-ALK translocation